Plus   Neg

Bristol-Myers Squibb Guides FY20 In Line With Estimates - Quick Facts

While reporting financial results for the fourth quarter on Thursday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) initiated earnings and revenue guidance for the full-year 2020, and earnings forecast for the full-year 2021.

For fiscal 2020, the company now projects earnings in a range of $0.75 to $0.95 per share and adjusted earnings in a range of $6.00 to $6.20 per share on revenues between $40.5 billion and $42.5 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $6.16 per share on revenues of $42.2 billion for the year. Analysts' estimates typically exclude special items.

The company also projected adjusted earnings for fiscal 2021 in a range $7.15 to $7.45 per share.

The company noted that all the guidance include the impact of the Celgene acquisition and the Otezla divestiture and assume current exchange rates.

Further, the company announced its board of directors approved an increase of $5 billion to the share repurchase authorization for the company's common stock. This is incremental to the current share repurchase program announced in October 2016 under which the company has approximately $1 billion remaining and increases the company's total outstanding share repurchase authorization under the company's share repurchase program to approximately $6 billion.

For the fourth quarter, the company reported a net loss attributable to Bristol-Myers Squibb of $1.06 billion, or $0.55 per share, compared to net earnings of $1.16 billion, or $0.71 per share in the prior-year quarter. Adjusted net earnings per share attributable to Bristol-Myers Squibb were $1.22, compared to last year's $0.94.

Bristol-Myers Squibb posted fourth-quarter revenues of $7.95 billion, an increase of 33 percent from the same period a year ago. Revenues increased 34 percent when adjusted for foreign exchange impact.

Analysts expected quarterly earnings of $0.88 per share on revenues of $6.14 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apotex Corp. recalled all lots of type 2 diabetes medication Metformin hydrochloride in the form of oral film-coated tablets for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Groupe Renault plans to cut about 14,600 jobs across the world and lower its production capacity. The plan includes almost 4,600 jobs reduction in France, through voluntary retirement and retraining. Amazon said it will convert 125,000 of the 175,000 temporary workers it hired in March amid the coronavirus pandemic, to permanent full-time employees in June. The e-commerce giant had hired the temporary employees in March to meet strong consumer demand amid the lockdown. The job openings were in Amazon's fulfillment centers and its delivery network.
Follow RTT